Andrew Blauvelt

Dr. Andrew Blauvelt, MD, MBA, is a Consultant at Blauvelt Consulting, LLC. He received his undergraduate degree in electrical engineering at Purdue University, his medical degree at Michigan State University, and a healthcare MBA at Oregon Health & Science University (OHSU).

Dr. Blauvelt trained in dermatology at the University of Miami and in cellular immunology under the direction of Dr. Steve Katz at the National Institutes of Health (NIH). Earlier in his career, he held senior staff positions at the NIH (Senior Investigator), OHSU (Professor), and the Portland VA Medical Center (Chief) as well as being Owner and President of Oregon Medical Research Center (OMRC) from 2013-2022.

Dr. Blauvelt’s research and clinical expertise has been in Langerhans cell biology, T cell immunology, virology, psoriasis, and atopic dermatitis. He has published over 375 papers and spoken across the country and world on these topics. Within psoriasis research, his laboratory published key papers on the role of IL-23/Th17 biology in this disease.

In recent years while at OMRC, he has been the international lead/senior investigator on a number of important clinical trials, including PSTELLAR, FEATURE, CLEAR, IXORA-R, VOYAGE 1, ECLIPSE, IMMhance, BE ABLE 1, BE ABLE 2, BE READY, BE RADIANT, OASIS-1, POETYK PSO-1, CHRONOS, ECZTEND, JADE REGIMEN, HEADS UP, ADhere, STRATUM, and KNOCKOUT.

Dr. Blauvelt is also an elected member of the American Society for Clinical Investigation, the International Psoriasis Council, and the International Eczema Council. In 2023, he became Chair of the Medical Board for the National Psoriasis Foundation, an organization he has worked closely with for over 20 years in a variety of capacities. For the past 3 years, Dr. Blauvelt made the lists of Highly Cited Researchers, representing the top 1% of cited scientists in the world.